ArticleLiver international : official journal of the International Association for the Study of the Liver2020
Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Revisiting the association between pretreatment thrombocytosis and cancer survival outcomes: an umbrella review of meta-analyses.BMC cancer · 2024Pooled it
- Platelet count as a prognostic biomarker in resected hepatocellular carcinoma: differential impact of thrombocytosis and thrombocytopenia by btiology and fibrosis.Surgery today · 2026Article
- Coronary artery disease and cancer: Shared risk factors, pathogenesis, and treatment effects.American heart journal plus : cardiology research and practice · 2026Review
- Clinical and pathophysiological perspectives on haemostasis, inflammation, and thrombo-haemorrhagic risk in cirrhosis.EXCLI journal · 2026Review
- Thrombotic Risk and Coagulation Imbalance in Cirrhosis and Hepatocellular Carcinoma: Clinical Implications and Management.Cancers · 2025Review
- The causal relationship between platelet indices and liver cancer: a bidirectional two-sample Mendelian randomization study.Discover oncology · 2025Article
- Features of the Therapy of Liver Cirrhosis in Aged Male and Female Rats.Bulletin of experimental biology and medicine · 2025Article
- Review
- Development and validation of a prealbumin-bilirubin model for prognostic prediction in intermediate hepatocellular carcinoma undergoing transarterial chemoembolization.Scientific reports · 2025Article
- Platelet C3G protects from liver fibrosis, while enhancing tumor growth through regulation of the immune response.The Journal of pathology · 2025Article
- Prognostic Significance of Elevated Platelet Count (>200 x 10^9 per L) in BCLC Stages B and C of Hepatocellular Carcinoma: A Retrospective Multicenter Analysis.Journal of hepatocellular carcinoma · 2025Article
- Preoperative platelet count as an independent predictor of long-term outcomes among patients undergoing resection for intrahepatic cholangiocarcinoma.Journal of surgical oncology · 2024Article
- Clinical Application of Different Liquid Biopsy Components in Hepatocellular Carcinoma.Journal of personalized medicine · 2024Review
- Article
- Peripheral blood platelet counts identify prognostically diverse clinical phenotypes in hepatocellular carcinoma.Annals of gastroenterology and the digestive system · 2024Article
- New and Old Key Players in Liver Cancer.International journal of molecular sciences · 2023Review
- Development of a machine learning-based model for predicting risk of early postoperative recurrence of hepatocellular carcinoma.World journal of gastroenterology · 2023Article
- The outcomes and prognostic factors of patients with hepatocellular carcinoma and Child-Turcotte-Pugh class B.Journal of the Chinese Medical Association : JCMA · 2023Article
- Article
- Genetic Analysis of Platelet-Related Genes in Hepatocellular Carcinoma Reveals a Novel Prognostic Signature and Determines PRKCD as the Potential Molecular Bridge.Biological procedures online · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 3 countries.
Funding
Abstract
BACKGROUND &
aimsThrombocytosis is associated with more aggressive tumour biology in many malignancies. There are limited data in patients with hepatocellular carcinoma (HCC), which often occurs in patients with cirrhosis and portal hypertension. We aimed to explore the prognostic value of thrombocytosis in two cohorts of patients with HCC.
methodsWe included 3561 patients from Taiwan and 1145 patients from the USA. Thrombocytopenia was defined as platelet count < 150×10
resultsThrombocytosis was present in 9.0% and 6.9% of Taiwan and USA patients respectively. Compared to patients with normal platelet counts and those with thrombocytopenia, patients with thrombocytosis had larger tumours, increased vascular invasion and a higher proportion had extrahepatic metastases in both cohorts. In multivariable analysis, thrombocytosis (aHR 1.40, 95% CI 1.23-1.60) and thrombocytopenia (aHR 1.13, 95% CI 1.04-1.23) were both associated with worse survival after adjusting for age, gender, liver disease aetiology, Child-Pugh score, maximal tumour size, tumour nodularity, vascular invasion, lymph node or distant metastasis, performance status and alpha-fetoprotein level. Patients with thrombocytosis had a median survival of 6 and 4 months in the Taiwan and USA cohorts, compared to 32 and 14 months for those with normal platelet counts and 38 and 16 months for thrombocytopenic patients.
conclusionThrombocytosis is independently associated with increased tumour burden and worse overall survival among HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.